Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination

Gevorg Tamamyan shared on LinkedIn:

“As I mentioned in my earlier post, we are ready in Armenia! I urge my dear friends at Agenus to consider Armenia as the first country to register BOT/BAL combination! We started the clinical trial for another indication – Non-Small Cell Lung Cancer (NCT06322108) just a month ago and in one month already 3 patients enrolled and 1 is in the process of enrollment! The team is ready and we will be happy to host and provide care for any patient from around the world! ”

Source: Gevorg Tamamyan/LinkedIn

Gevorg Tamamyan is the Editor-in-chief of OncoDaily, Chairman and Professor of the Department of Hematology and Pediatric Oncology at Yerevan State Medical University, CEO of the Immune Oncology Research Institute, President-Elect of the Pediatric Oncology East and Mediterranean (POEM) Group.

He is also the Adviser to the Rector of YSMU and to the Director of the Yeolyan Hematology and Oncology Center.

He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.